Valneva announces publication of its covid-19 vaccine phase 3 data in the lancet infectious diseases

Saint- herb lain (france ) , september 6 , 2 02 2 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announces that the lancet infectious diseases (“the lancet id ”), a peer-reviewed medical journal, has published the company's pivotal phase 3 clinical data for its inactivated, whole-virus covid-19 vaccine, vla2001.
VALN Ratings Summary
VALN Quant Ranking